 | Up a level |
Journal Article
Behringer, K., Goergen, H., Borchmann, P., Diehl, V., Fuchs, M., Lohri, A., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., Topp, M. S., Soekler, M., Mathas, S., Meissner, J., von Tresckow, B., Boell, B. and Engert, A. (2014). IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., Halbsguth, T., Eichenauer, D. A., Fuchs, M., Reiners, K. S., Renno, J. H., van der Ven, K., Kuehr, M., von Wolff, M., Diehl, V., Engert, A. and Borchmann, P. (2020). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial (vol 23, pg 1818, 2012). Ann. Oncol., 31 (8). S. 1093 - 1094. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Boell, B., Pluetschow, A., Eichenauer, D., von Tresckow, B., Atta, J., Pfreundschuh, M., Michaela, F. B., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2015). GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS-FINAL ANALYSIS. Haematologica, 100. S. 322 - 323. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Boell, B., Pluetschow, A., Eichenauer, D. A., Thielen, I, von Tresckow, B., Atta, J., Pfreundschuh, M., Feuring-Buske, M., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2014). German Hodgkin Study Group Phase I trial of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) for elderly Hodgkin Lymphoma patients. Oncol. Res. Treat., 37. S. 12 - 13. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Eichenauer, D., Pluetschow, A., Kreissl, S., Fuchs, M., Soekler, M., Engel, N., Mathas, S., Behringer, K., Kobe, C., Dietlein, M., Diehl, V. and Engert, A. (2014). TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY. Haematologica, 99. S. 497 - 499. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Borchmann, S., Goergen, H., Sasse, S., Kreissl, S., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Diehl, V. and Engert, A. (2018). Pretreatment vitamin D deficiency is associated with lower progression free and overall survival in prospectively treated Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 273 - 275. BASEL: KARGER. ISSN 2296-5262
Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M., Borchmann, P. and Engert, A. (2016). OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA: THE GERMAN HODGKIN STUDY GROUP EXPERIENCE. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M. and Engert, A. (2016). OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG). Haematologica, 101. S. 5 - 7. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, S., Mueller, H., Hude, I, Fuchs, M., Borchmann, P. and Engert, A. (2019). Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann. Oncol., 30 (8). S. 1329 - 1335. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Broeckelmann, P. J., Goergen, H., Fuchs, M., Eich, H. T., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2016). Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: Experience of the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 39. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 46 - 48. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 320 - 321. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Pluetschow, A., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS. Haematologica, 101. S. 4 - 5. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Mueller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., Moskowitz, C. H. and Engert, A. (2017). Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol., 28 (6). S. 1352 - 1359. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS. Haematologica, 101. S. 146 - 148. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P. J., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HL SURVIVORS ON TREATMENT-ASSOCIATED BURDENS AND SIDE EFFECTS. Haematologica, 101. S. 61 - 62. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Cavcic, M., Oschlies, I., Fuchs, M., Engert, A. and Klapper, W. (2017). Recovery of paraffin blocks and central archiving. Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma. Pathologe, 38 (6). S. 529 - 535. NEW YORK: SPRINGER. ISSN 1432-1963
Dietlein, M., Kuhnert, G., Semrau, R., Nast-Kolb, B., Baues, C., Fuchs, M., Drzezga, A. and Kobe, C. (2014). Current importance of positron emission tomography in Hodgkin's lymphoma. Onkologe, 20 (5). S. 429 - 439. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Eich, H. T., Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Pluetschow, A., Fuchs, M., Engert, A. and Baues, C. (2016). FINAL RESULTS OF A QUALITY ASSURANCE PROGRAM WITHIN THE GERMAN HODGKIN STUDY GROUP HD13/14 TRIAL - A REPORT FROM THE RADIOTHERAPY REFERENCE PANEL INTEGRATING MODERN GUIDELINES. Haematologica, 101. S. 14 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Eichenauer, D. A., Kreissl, S., Buehnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., von Tresckow, B., Engert, A. and Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 32 (6). S. 807 - 811. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Eichenauer, D. A., Kreissl, S., Buehnen, I., Goergen, H., Hartmann, S., Fuchs, M., von Tresckow, B., Engert, A. and Borchmann, P. (2020). PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 87 - 89. BASEL: KARGER. ISSN 2296-5262
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Borchmann, P. and Engert, A. (2017). Long-term outcome of patients with early-stage nodular lymphocyte-predominant hodgkin lymphoma (NLPHL) treated within the randomized HD7, HD10 and HD13 trials: An analysis from the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 40. S. 142 - 143. BASEL: KARGER. ISSN 2296-5262
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Diehl, V., Borchmann, P. and Engert, A. (2017). LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 82 - 83. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Gillessen, S., Pluetschow, A., Fuchs, M., Markova, J., Greil, R., Topp, M., Meissner, J., Zijlstra, J., Eichenauer, D., Broeckelmann, P., Diehl, V., Borchmann, P., Engert, A. and von Tresckow, B. (2020). Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 88 - 90. BASEL: KARGER. ISSN 2296-5262
Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V and Kunzmann, V (2022). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open, 7 (4). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Hartlapp, I., Valta-Seufzer, D., Siveke, J., Alguel, H., Goekkurt, E., Siegler, G. M., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C-T., Stang, H. A., Heinemann, V. and Kunzmann, V. (2021). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). Ann. Oncol., 32. S. S1091 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Hay, A. E., Klimm, B., Chen, B. E., Goergen, H., Shepherd, L. E., Fuchs, M., Gospodarowicz, M. K., Borchmann, P., Connors, J. M., Markova, J., Crump, M., Lohri, A., Winter, J. N., Doerken, B., Pearcey, R. G., Diehl, V., Horning, S. J., Eich, H. T., Engert, A. and Meyer, R. M. (2013). An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann. Oncol., 24 (12). S. 3065 - 3070. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Klimm, B., Goergen, H., Fuchs, M., von Tresckow, B., Boell, B., Meissner, J., Glunz, A., Diehl, V., Eich, H. T., Engert, A. and Borchmann, P. (2013). Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann. Oncol., 24 (12). S. 3070 - 3077. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Kobe, C., Dietlein, M., Borchmann, P., Engert, A., Kuhnert, G., Fuchs, M., Haverkamp, H., Eich, H. T., Kriz, J. and Diehl, V. (2011). PET-Response Adapted Therapy in Hodgkin Lymphoma. Eur. J. Cancer, 47. S. S16 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049
Kobe, C., Goergen, H., Fuchs, M., Eich, H. T., Baues, C., Diehl, V., Kuhnert, G., Drzezga, A., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S312 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfart, K., Lukas, P., Pluetschow, A., Schmidberger, H., Staar, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). Quality control of involved field radiotherapy in the HD 13 and HD 14 trials. Strahlenther. Onkol., 193 (2). S. 109 - 116. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Marnitz-Schulze, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). New quality assurance program integrating modern radiotherapy within the German Hodgkin Study Group. Strahlenther. Onkol., 193 (2). S. 100 - 109. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Klimm, B., Goergen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., Koch, O., Wilhelm, M., Trenn, G., Finke, J., Mueller, R. P., Diehl, V., Eich, H. T., Borchmann, P. and Engert, A. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol., 23 (11). S. 2953 - 2960. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534
Soehngen, D., Balzer, C., Fuchs, M. and Waldschmidt, D. (2015). Rehabilitation of Patients with Acid-base and Fluid Balance Disorders with Short Bowel Syndrome after Ileostomies. Rehabilitation, 54 (2). S. 86 - 92. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-1309
Soehngen, D., Balzer, C., Fuchs, M. and Waldschmidt, D. (2015). Rehabilitation of Patients with Acid-base and Fluid Balance Disorders with Short Bowel Syndrome after Ileostomies. Rehabilitation, 54 (2). S. 86 - 92. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-1309
Thurner, L., Hartmann, S., Kemele, M., Fadle, N., Regitz, E., Kim, Y. -J., Bohle, R. M., Nimmesgern, A., von Mueller, L., Schneider, N., Vornanen, M., Sundstroem, C., de Leval, L., Fuchs, M., Engert, A., Kempf, V. A. J., Kueppers, R., Preuss, K. D., Hansmann, M. -L. and Pfreundschuh, M. (2017). The role of Moraxella in the pathogenesis of IgD(+) nodular lymphocyte predominant Hodgkin lymphoma. Oncol. Res. Treat., 40. S. 143 - 144. BASEL: KARGER. ISSN 2296-5262
Voltin, C., Stockter, S., Baues, C., Fuchs, M., Dietlein, M., Mettler, J., Engert, A., Borchmann, P., Drzezga, A. and Kobe, C. (2017). Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of F-18-FDG PET? Eur. J. Nucl. Med. Mol. Imaging, 44. S. S244 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Voltin, C. -A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M. and Kobe, C. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann. Oncol., 29 (9). S. 1926 - 1932. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041